MGI Aloxi Oral Dose, Post-Operative Indications To Enter Phase III In 2004
Executive Summary
MGI Pharma plans to commence Phase III trials for an oral formulation of the intravenous anti-emetic Aloxi (palonosetron), as well as studies supporting a post-operative indication